Dr. Reddy’s Laboratories Ltd. on Tuesday announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide capsules, from the U.S. Food and Drug Administration (USFDA).
According to a press release issued by the city-based drug maker, the FDA approved Lenalidomide capsules in 2.5 mg and 20 mg strengths, and gave tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths. Lenalidomide is used to treat various types of cancers.
With this approval, Dr. Reddy’s is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg, it said. In September 2020, Dr. Reddy’s announced a settlement agreement of their litigation with Celgene, the maker of Revlimid (lenalidomide) capsules and a wholly-owned subsidiary of Bristol Myers Squibb relating to patents for the branded drug.
”We are pleased with the Agency’s approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity. We look forward to bringing a more affordable generic version of this drug to market for the benefit of patients,” Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories said.
In settlement of all outstanding claims in the litigation, Celgene agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval.
The agreed-upon percentages remain confidential. As part of the settlement, Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning January 31, 2026, the release said.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.